Direct Oral Anticoagulant–Calibrated Heparin LRT Assay as a Rapid Alternative to an Anti‐Factor Xa Assay for Measuring Apixaban, Edoxaban, and Rivaroxaban in Patients With Non‐Valvular Atrial Fibrillation

In a Nutshell: Testing DOAC Levels—When, Why and What It Means?

10.1111/bjh.70313 · 2026

Measuring Direct Oral Anticoagulant (DOAC) Levels: Applications, Limitations, and Future Directions

10.1111/ijlh.14483 · 2026

An Update on Laboratory Assessment for Direct Oral Anticoagulants

10.1111/ijlh.12992 · 2019

Monitoring of Direct Oral Anticoagulants Plasma Levels for Secondary Stroke Prevention

10.1111/jth.15677 · 2022

International Council for Standardization in Haematology (ICSH) Recommendations for Laboratory Measurement of Direct Oral Anticoagulants

10.1055/s-0038-1627480 · 2018

2021 Update of the International Council for Standardization in Haematology Recommendations for Laboratory Measurement of Direct Oral Anticoagulants

10.1055/a-1450-8178 · 2021

Laboratory Testing in Patients Treated With Direct Oral Anticoagulants: A Practical Guide for Clinicians

10.1111/jth.13912 · 2018

Usefulness of Heparin Calibrated Anti‐Xa Activity to Assess Anticoagulant Activity of Apixaban and Rivaroxaban in Emergency Patients Scheduled for Acute Interventions

10.3390/jcm12216785 · 2023

Using a Low‐Molecular Weight Heparin‐Calibrated Anti‐Factor Xa Assay to Assess the Concentration of Apixaban and Rivaroxaban